IMRX - Immuneering Appoints Thomas J. Schall Ph.D. to its Board of Directors | Benzinga
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.
"On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization efforts at ChemoCentryx, will be highly impactful as we continue to move closer towards our goal of developing medicines with broad activity for large populations of cancer patients."
"I am delighted to join the Immuneering board at this exciting time as the company ...